Saxenda (liraglutide 3 mg) / Novo Nordisk - LARVOL DELTA

The effect of weight loss and glucagon-like peptide-1 receptor agonist on structural changes in knee osteoarthritis: secondary analysis of the randomised, placebo-controlled LOSEIT trial (EULAR 2025) - "If successfully achieving at least a 5% weight loss (during an 8-week intensive dietary intervention (IDI) period) participants were randomised to receive either subcutaneously administered liraglutide 3 mg/day or identically appearing placebo throughout the 52-week main trial period (weeks 0 through 52; i.e., 60 weeks in total)... While the results partially indicate a potentially favourable effect in the GLP-1RA group, the observed difference in structural knee OA changes on radiographs compared to placebo did not reach statistical significance. Further research should investigate whether treatment with more potent GLP-1 receptor agonists could lead to a more substantial improvement in structural knee OA."

Clinical • Genetic Disorders • Immunology • Musculoskeletal Pain • Obesity • Orthopedics • Osteoarthritis • Pain • Rheumatology

Effect of Meal Replacement Compared with Liraglutide 3.0 mg on Weight Loss and Hepatic Steatosis before Bariatric Surgery—A Randomised Study (ADA 2025) - "Liraglutide achieved numerically greater, albeit non-significant improvement of weight and non-invasive markers of MAFLD after an 18-week intervention prior to bariatric surgery compared to a dietary intervention with a meal replacement product."

Bariatric surgery • Clinical • Surgery • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Effects of Liraglutide on Body Composition Distribution in Adolescents with Refractory Obesity Post-Vertical Sleeve Gastrectomy (ENDO 2025) - "Liraglutide 3.0 mg/d for 16 weeks reduced total and subcomponent fat and lean mass in adolescents with obesity post-VSG. 35% of all weight lost was lean mass. Change in trunk fat mass was positively correlated with liraglutide-associated change in fasting glucose."

Gastrointestinal Disorder • Genetic Disorders • Obesity

Pregnancy warning to women taking Ozempic and Mounjaro after ‘baby boom’ (The Independent) - "Women using weight-loss injections are being urged to use effective contraception, following the Medicines and Healthcare products Regulatory Agency (MHRA)'s first public alert on the use of contraception alongside weight loss and diabetes jabs. The MHRA issued the warning amid concerns that the medications may not be used safely. There have been previous reports linking the injections to a 'baby boom,' with some women reporting unexpected pregnancies, dubbed 'Ozempic babies,' despite using contraception. To date, the MHRA has received over 40 reports of pregnancies among women using these drugs. The drugs in question include Ozempic, Mounjaro, Wegovy, Saxenda, and Victoza, all of which are glucagon-like peptide-1 receptor agonists (GLP-1 or GLP-1 RAs)."

Commercial • Obesity • Type 2 Diabetes Mellitus

Maximizing Outcomes: Synchronizing Liraglutide And Tailored Exercise In Weight Loss - A Case Study (ACSM 2025) - "X began on an incremental protocol of liraglutide (Saxenda), starting at 0.6 mg daily and gradually increasing to the maximum dose of 3 mg daily over several weeks. A comprehensive metabolic panel revealed normal thyroid and glucose levels, ruling out hypothyroidism and Type 2 Diabetes. Exercise testing showed:VT VO2: 17.6 ml/kg/minVT HR: 114 bpmVO2 Max: 36.8 ml/kg/minMax HR: 177 bpmBody composition and anthropometric measures, including weekly neck, arm, waist, and hip circumferences, were recorded to track progress. FINAL WORKING DIAGNOSIS: The final diagnosis was primary obesity complicated by central adiposity and functional limitations.TREATMENT AND OUTCOMES:Mr."

Case study • Clinical • Cardiovascular • Diabetes • Endocrine Disorders • Fatigue • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Obesity • Orthopedics • Pain • Type 2 Diabetes Mellitus

Symptomatic adverse events and patient-reported outcomes related to incretin-based medicines for obesity: a systematic review involving >400, 000 subjects (ECO 2025) - "Treatment arms for the maintenance dose (or highest dose where maintenance was not used) were selected (e.g. liraglutide 3 mg, semaglutide 2.4 mg, and tirzepatide 15 mg), where a study had more than one treatment arm for the same IBT. This systematic review of the literature confirms that GI AEs are the most commonly reported symptomatic AEs, and that their incidence varies between IBTs and studies. Clinicians should keep the AE profile of IBTs in mind when making therapy decisions and consider mitigation strategies including nutritional solutions. Abbreviations: AE, adverse event; IBT, incretin-based therapy; N, number of patients; n, number of publications; RWE, real-world evidence."

Adverse events • Clinical • Patient reported outcomes • Review • Alopecia • Constipation • Fatigue • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Obesity • Pain

The effects of a two-week hypocaloric meal replacement compared to an established liraglutide therapy on body composition and non-invasive markers of MAFLD before bariatric surgery (ECO 2025) - " We investigated the effects of a hypocaloric, high-fiber, high-protein diet based on three daily meal replacement products (Hepafast®) compared to a treatment with liraglutide 3.0 mg, which had already been initiated 16 weeks earlier as part of the preparation for bariatric surgery. 49 patients (age 40±11yrs, BMI 44.6±5.6 kg/m², 78% women) were included. At baseline, the liraglutide group had a numerically, but not significantly lower weight (p=0.193), BMI (p=0.206) and waist circumference (p=0.236) compared to the meal replacement group. Mean weight loss after 2 weeks was significantly greater in the meal replacement group (p=0.019)."

Bariatric surgery • Non-invasive • Surgery • Genetic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Exercise improves cardiorespiratory fitness and functional performance during weight loss maintenance with GLP-1 receptor agonist treatment (ECO 2025) - P4 | " This is a secondary analysis of the S-LiTE trial (NCT04122716), which involved 195 adults with obesity who completed an 8-week low-calorie diet and were subsequently randomized (1:1:1:1 ratio) into four groups for 52 weeks: moderate-to-vigorous-intensity exercise program plus placebo (exercise alone), GLP-1 RA liraglutide 3 mg once-daily plus usual activity (liraglutide alone), exercise plus liraglutide (combination treatment), or placebo plus usual activity (placebo)... Moderate-to-vigorous-intensity exercise during GLP-1 RA treatment for weight maintenance improved cardiorespiratory fitness and functional performance and increased relative muscle strength despite additional weight loss. In contrast, GLP-1 RA treatment alone did not improve cardiorespiratory fitness nor functional performance. These findings highlight the importance of incorporating structured exercise into medical obesity treatments to optimize physical fitness and function during weight loss..."

Clinical • Genetic Disorders • Obesity

Maximizing outcomes: synchronizing liraglutide and tailored exercise in weight loss - a case study (ECO 2025) - "The patient was placed on a progressive liraglutide (Saxenda) protocol, titrated up to 3 mg daily, complemented by a customized exercise regimen totaling 300 minutes per week. The results suggest that personalized exercise can amplify the effects of liraglutide, fostering weight loss and improved physical capacity. The findings support a combined intervention approach for individuals with long-standing obesity who have struggled with lifestyle modification alone, underscoring the value of individualized, dual-modality treatment for achieving and sustaining weight loss while improving overall fitness and health outcomes."

Case study • Clinical • Cardiovascular • Diabetes • Endocrine Disorders • Fatigue • Genetic Disorders • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Obesity • Orthopedics • Pain • Type 2 Diabetes Mellitus

Real-world data on the effectiveness of liraglutide (Saxenda) and naltrexone/bupropion (Mysimba) on weight loss outcomes up to 2 years in clinical practice (ECO 2025) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world evidence

LITOP: Liraglutide Treatment in Obese Infertile PCOS Women (clinicaltrials.gov) - P4 | N=890 | Recruiting | Sponsor: Peking University Third Hospital | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2028 ➔ Dec 2029 | Initiation date: Feb 2025 ➔ May 2025 | Trial primary completion date: Jun 2028 ➔ May 2029

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Genetic Disorders • Infertility • Obesity • Polycystic Ovary Syndrome • Sexual Disorders

Saxenda - opinion on variation to marketing authorisation (European Medicines Agency) - "On 22 May 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Saxenda. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S...The CHMP adopted an extension to the existing indication to include treatment of children aged 6 to less than 12 years, as follows: Children (6 to <12 years): Saxenda is indicated as an adjunct to healthy nutrition and increased physical activity for weight management in children from the age of 6 to <12 years with: obesity (BMI ≥95th percentile) and body weight ≥45 kg....Treatment with Saxenda should be discontinued and re-evaluated if patients have not lost at least 4% of their BMI or BMI z score after 12 weeks on the 3.0 mg/day or maximum tolerated dose."

CHMP • Obesity

Analysis of Employer Coverage of Weight Loss Therapies (ISPOR 2025) - "71% of workers have access to Wegovy through their employer, and 54% have access to Saxenda. This analysis will help policymakers gain a better understanding of employee coverage decisions so they can develop optimal policies that balance the financial costs against the health and economic benefits of weight loss therapies. Further research is needed on the drivers behind the correlations presented in this analysis. The findings will also help manufacturers conduct out-reach to employers, and appeal to their unique needs, such as the ability to compete for talent and prevention of morbidities that can hinder the ability to work."

Genetic Disorders • Obesity

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. (PubMed, Neurol Ther) - " Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized."

Journal • Review • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease

Real-world use of liraglutide for weight management according to label in the United Kingdom: A cohort study using the Clinical Practice Research Datalink primary care databases. (PubMed, Diabetes Obes Metab) - "This DUS provides descriptive data for initiators of liraglutide in the initial 5-year period following the launch of Saxenda® in the United Kingdom. Real-world use of Saxenda® and Victoza® raised no new safety concerns. Where assessment was possible, Saxenda® and Victoza® were mostly prescribed by physicians according to their approved indications."

Journal • Real-world evidence • Diabetes • Genetic Disorders • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluating GLP-1 receptor agonists in treating pediatric obesity within the context of social determinants of health: A systematic review and meta-analysis (PAS 2025) - "Although Wegovy (semaglutide) and Saxenda (liraglutide) have been FDA-approved, public insurance programs like Medicaid do not cover their costs. Eight RCTs were included in this review (N = 711; ages 6-19). The combined Hedges’ g values were: -0.32 (95% confidence interval: [−0.49, −0.15]) for BMI, -0.34 (−0.51, −0.18) for BMI-SDS, and -0.35 (−0.50, −0.19) for weight change, indicating small to moderate reductions in these measures for treatment groups. Conclusion(s) : This meta-analysis highlights a significant treatment effect of GLP-1RAs on pediatric obesity."

Retrospective data • Review • Diabetes • Genetic Disorders • Obesity • Pediatrics

A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland. (PubMed, Value Health) - "The MAP facilitates access for a subpopulation in whom liraglutide is effective and also expected to be most cost-effective, according to HTA."

Journal • Observational data • Retrospective data

Institute for Clinical and Economic Review Releases Obesity Medications White Paper Examining Strategies to Ensure Affordable Access (Institute for Clinical and Economic Review) - "The Institute for Clinical and Economic Review (ICER), in collaboration with researchers from Brown University, has published a new white paper today that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications. The paper, entitled, “Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions,” seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications."

HEOR • Obesity

Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review. (PubMed, Cureus) - "This literature review evaluates and compares the effectiveness of four pharmacological agents semaglutide, liraglutide, orlistat, phentermine, and emerging agents like setmelanotide, amycretin, retatrutide, cagrilintide, and cotadutide in managing weight loss among obese. A detailed analysis was conducted on their mechanisms of action, dosing regimens, efficacy in weight loss, safety profiles, and their impact on obesity-related comorbidities. Although all agents presented distinct benefits, side effects such as gastrointestinal discomfort with orlistat and GLP-1 receptor agonists, and potential dependency with phentermine, necessitate tailored treatment approaches. This review highlights the importance of integrating pharmacotherapy with lifestyle interventions to achieve sustainable weight management and identifies areas for future research to optimize therapeutic outcomes for individuals with obesity."

HEOR • Journal • Review • Cardiovascular • Gastrointestinal Disorder • Genetic Disorders • Obesity

“Extension of indication to include the use of SAXENDA for weight management in children from the age of 6 years to less than 12 years based on results from study NN8022- 4392… as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 34.0 of the RMP has also been submitted” (European Medicines Agency) - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of meeting on 10 – 13 Feb 2025

PRAC • Obesity

Saxenda: Newly added patents in Orange Book (Orange Book) - Expiry on Oct 20, 2025, Jan 20, 2026, Apr 20, 2026, Jul 17, 2026, Jul 20, 2026, Jul 26, 2026, Aug 3, 2026, Jan 17, 2027, Feb 3, 2027, Feb 27, 2027, Aug 27, 2027, Sep 27, 2027, Mar 27, 2028, Feb 1, 2032, Aug 1, 2032

Patent • Metabolic Disorders • Obesity

Study to Evaluate the Safety and Effectiveness of Saxenda® for Weight Management in Routine Clinical Practice in Taiwan. (clinicaltrials.gov) - P=N/A | N=288 | Completed | Sponsor: Novo Nordisk A/S | Active, not recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

Saxenda: Underlying Mechanisms and Clinical Outcomes (clinicaltrials.gov) - P4 | N=28 | Active, not recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) AND OBESITY, THE USE OF LIRAGLUTIDE, DECREASES VISCERAL ABDOMINAL FAT, AND INCREASES OVULATION RESUMPTION (ATTD 2025) - "Background and Aims: Anovulatory PCOS in obese women is usually managed with a lifestyle program + metformin, but is often unsatisfactory. In anovulatory women with PCOS and obesity, liraglutide 3.0 mg/die was effective in decreasing VAT and increasing ORR. An early and consistent VAT loss is related to ovulation resumption. Future studies should address the mechanisms behind these changes and evaluate interventions aimed at VAT reduction to facilitate ovulation resumption."

Clinical • Genetic Disorders • Obesity • Polycystic Ovary Syndrome

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. (PubMed, Expert Opin Investig Drugs) - "Liraglutide 3.0 mg daily, the first GLP-1 RA approved for treatment of overweight, induced a weight loss of 6-8%, Semaglutide 2.4 mg once weekly improved weight loss to about 12-15%, while the dual GIP/GLP-1 receptor agonist tirzepatide once weekly has induced a weight loss of about 20% in obese people without diabetes. This review describes results obtained with GLP-1 mono-agonists, GLP-1/GIP dual agonists, GLP-1/glucagon co-agonists, and the triple agonist retatrutide (GIP/GLP-1/glucagon), which have shown beneficial effect both on body weight and steatotic liver disease. A combination of semaglutide (a GLP-1 agonist) and cagrilintide (a long-acting amylin analogue) for weekly administration is currently in phase III development, and so is oral semaglutide and several non-peptide small molecule GLP-1 agonists for oral administration...The GLP-1-based therapies will change the treatment of obesity and its comorbidities including steatotic liver disease in the future...."

Journal • P2 data • Review • Diabetes • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity